Author Contributions: Dr Strickler had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Keller, Burk, Massad, Palefsky, Strickler.
Acquisition of data: Burk, Anastos, Massad, Minkoff, Levine, Strickler.
Analysis and interpretation of data: Keller, Burk, Xie, Massad, Xue, D’Souza, Watts, Castle, Colie, Strickler.
Drafting of the manuscript: Keller, Xie, Massad, Xue, Palefsky, Strickler.
Critical revision of the manuscript for important intellectual content: Keller, Burk, Xie, Anastos, Massad, Minkoff, Xue, D’Souza, Watts, Levine, Castle, Colie, Palefsky, Strickler.
Statistical analysis: Keller, Xie, Xue, D’Souza, Strickler.
Obtained funding: Burk, Anastos, Minkoff, Levine, Palefsky, Strickler.
Administrative, technical, or material support: Burk, Watts, Castle, Colie, Strickler.
Study supervision: Burk, Anastos, Minkoff, Levine, Strickler.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Castle reported receiving fees from Merck Sharp & Dohme for serving as a member of a data and safety monitoring board. Dr Palefsky reported receiving grant support, as well as travel support and fees for review activities, through his institution from Merck Sharp & Dohme; receiving fees through his institution for serving as a board member and consultant and providing expert testimony for Merck Sharp & Dohme; and serving as a member of the scientific advisory board of Pharmajet. No other authors reported disclosures.
Funding/Support: Support for this study, including HPV DNA testing, was provided through R01-CA-085178. Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS) Collaborative Study Group with centers (principal investigators) at New York City/Bronx Consortium (Dr Anastos); Brooklyn, New York (Dr Minkoff); Washington, DC, Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium (Dr Levine); Chicago Consortium (Mardge Cohen); Data Coordinating Center (Stephen Gange). The WIHS is funded by the National Institute of Allergy and Infectious Diseases (U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-AI-34993, and U01-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) (U01-HD-32632). The study is cofunded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI grant UL1 RR024131). Additional support was provided by R33-AI079763, the Einstein-Montefiore Center for AIDS Research (P30-AI-51519), and the Institute for Clinical and Translational Research (UL1 RR025750).
Role of the Sponsor: The WIHS is a National Institutes of Health (NIH)–funded multicenter cohort study. Thus, the funding sources had a role in the overall WIHS study design but not the design of the current ancillary study; one coauthor, Dr Watts, is an employee of NICHD/NIH, and as an author had a role in the interpretation of the current data, and she reviewed and approved the submitted manuscript.
Disclaimer: The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.
Previous Presentation: Presented in part at the 2011 International Papillomavirus Conference; September 17-22, 2011; Berlin, Germany.